


## Supplementary Methods

For qRT-PCR, the following gene-specific primers were used: *Ifnb1*, 5'-TCCGAGCAGAGATCTTCAGGAA-3' (forward) and 5'-TGCAACCACCACTCATTCTGAG-3' (reverse); *Isg15*, 5'-AAGAAGCAGATTGCCCAGAA-3' (forward) and 5'-TCGCTGCAGTTCTGTACCAC-3' (reverse); *Mda5* (a.k.a., *Ifih1*), 5'-ACAGAGGCCTGGAACGTAGA-3' (forward) and 5'-TTCATCGAAGCAGCTGACAC-3' (reverse); *Ifit1* (a.k.a., *Isg56*), 5'-AGGCTGGAGTGTGCTGAGAT-3' (forward) and 5'-AGGGTTTTCTGGCTCCACTT-3' (reverse). The relative abundance of each gene transcript was normalized to that of 28S rRNA.

For immunoblotting, the following primary antibodies were used for immunodetection: rabbit anti-MDA5 and mouse anti-GAPDH (Proteintech, Rosemont, IL), mouse anti-ISG15 (Santa Cruz, Dallas, TX), and mouse anti-beta-ACTIN (ABclonal, Woburn, MA). Protein bands were visualized following incubation with appropriate IRDye<sup>®</sup>-labelled secondary antibodies and their signal intensity quantified using Image Studio Lite (LI-COR Biosciences, Lincoln, NE) and normalized to that of beta-ACTIN.

## Supplementary Figure

### (Figure S1)



**Figure S1. TRIM56 potentiates the establishment of an antiviral state against VSV-Luc challenge by LPS pre-stimulation.** B6Mφ cells with and without human TRIM56 expression were mock-stimulated or stimulated by 1 µg/ml LPS for 8 h, followed by mock infection or infection by VSV-Luc (MOI=0.1). Eight hours later, cells were lysed for firefly luciferase assay. \*\* and \*\*\* denote  $p < 0.01$  and  $p < 0.001$ , respectively (One-way ANOVA).